Senseonics (NYSE:SENS) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS) in a research note issued on Wednesday. The brokerage set a “sell” rating on the stock.

Senseonics Price Performance

Shares of NYSE SENS opened at $0.39 on Wednesday. The company has a quick ratio of 3.70, a current ratio of 3.96 and a debt-to-equity ratio of 1.79. The company has a market cap of $208.64 million, a P/E ratio of -2.81 and a beta of 0.82. Senseonics has a 52 week low of $0.37 and a 52 week high of $1.05. The business has a 50-day simple moving average of $0.44 and a two-hundred day simple moving average of $0.52.

Senseonics (NYSE:SENS) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03). The company had revenue of $5.05 million during the quarter, compared to analyst estimates of $4.76 million. Senseonics had a negative net margin of 346.38% and a negative return on equity of 202.32%. Research analysts anticipate that Senseonics will post -0.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Senseonics

Institutional investors have recently made changes to their positions in the stock. RPO LLC purchased a new position in Senseonics in the fourth quarter worth $37,000. Price T Rowe Associates Inc. MD increased its position in shares of Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after purchasing an additional 51,000 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Senseonics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after purchasing an additional 155,715 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Senseonics during the 1st quarter valued at about $162,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in Senseonics in the 1st quarter worth approximately $91,000. Institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.